BR112013011041A2 - variante de fator viii, polinucleotídeo, vetor de expressão, célula de mamífero, métodos para produzir uma variante de fviii e para tratar um paciente que sofre de hemofilia, e, composição farmacêutica - Google Patents

variante de fator viii, polinucleotídeo, vetor de expressão, célula de mamífero, métodos para produzir uma variante de fviii e para tratar um paciente que sofre de hemofilia, e, composição farmacêutica

Info

Publication number
BR112013011041A2
BR112013011041A2 BR112013011041A BR112013011041A BR112013011041A2 BR 112013011041 A2 BR112013011041 A2 BR 112013011041A2 BR 112013011041 A BR112013011041 A BR 112013011041A BR 112013011041 A BR112013011041 A BR 112013011041A BR 112013011041 A2 BR112013011041 A2 BR 112013011041A2
Authority
BR
Brazil
Prior art keywords
variant
hemophilia
polynucleotide
treating
producing
Prior art date
Application number
BR112013011041A
Other languages
English (en)
Other versions
BR112013011041B1 (pt
Inventor
Kong Lai Chee
Kevin Staford Roddy
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Publication of BR112013011041A2 publication Critical patent/BR112013011041A2/pt
Publication of BR112013011041B1 publication Critical patent/BR112013011041B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112013011041-4A 2010-11-05 2011-11-04 variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica BR112013011041B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41043710P 2010-11-05 2010-11-05
US61/410437 2010-11-05
PCT/US2011/059297 WO2012061689A2 (en) 2010-11-05 2011-11-04 A new variant of antihemophilic factor viii having increased specific activity

Publications (2)

Publication Number Publication Date
BR112013011041A2 true BR112013011041A2 (pt) 2017-06-06
BR112013011041B1 BR112013011041B1 (pt) 2021-05-25

Family

ID=46025129

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013011041-4A BR112013011041B1 (pt) 2010-11-05 2011-11-04 variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica

Country Status (18)

Country Link
US (2) US9150637B2 (pt)
EP (1) EP2635297B1 (pt)
JP (1) JP5922141B2 (pt)
KR (1) KR101948337B1 (pt)
CN (1) CN103298483B (pt)
AU (1) AU2011323236B2 (pt)
BR (1) BR112013011041B1 (pt)
CA (1) CA2816575C (pt)
CO (1) CO6720990A2 (pt)
DK (1) DK2635297T3 (pt)
EA (1) EA035447B1 (pt)
ES (1) ES2721478T3 (pt)
IL (1) IL226158B (pt)
MX (2) MX351220B (pt)
MY (1) MY165089A (pt)
SG (2) SG10201509149VA (pt)
WO (1) WO2012061689A2 (pt)
ZA (1) ZA201303816B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016123200A1 (en) 2015-01-30 2016-08-04 Emory University Factor viii proteins having ancestral sequences, expression vectors, and uses related thereto
EP3476860A4 (en) 2016-06-24 2020-01-22 Mogam Institute for Biomedical Research RECOMBINANT SINGLE CHAIN FVIII AND CHEMICAL CONJUGATE THEREOF

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en) 1984-08-24 1987-10-28 Genetics Institute, Inc. Production of factor viii and related products
EP0218712B1 (en) 1985-04-12 1992-02-26 Genetics Institute, Inc. Novel procoagulant proteins
JPS6281327A (ja) 1985-10-04 1987-04-14 Green Cross Corp:The 人トロンビン製剤の加熱処理方法
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
JPS6485927A (en) 1987-09-29 1989-03-30 Green Cross Corp Hepatitis b vaccine
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
JPH0626980Y2 (ja) 1987-11-26 1994-07-20 ソニー株式会社 誤消去防止機構
WO1989009784A1 (en) 1988-04-08 1989-10-19 Commonwealth Serum Laboratories Commission Production of heat-stable factor viii concentrate
DK162233C (da) 1989-11-09 1992-03-16 Novo Nordisk As Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
US5384132A (en) 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5888974A (en) 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) 1996-06-26 2001-01-30 Emory University Modified factor VIII
CZ290342B6 (cs) 1992-10-02 2002-07-17 Genetics Institute Inc. Kompozice stabilní při skladování, obsahující koagulační faktor VIII a neiontovou povrchově aktivní látku a způsob její výroby
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
EP0710288B1 (en) 1993-06-10 2006-04-05 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
ZA955642B (en) 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
JPH0899999A (ja) 1994-09-30 1996-04-16 Chemo Sero Therapeut Res Inst α１プロテアーゼインヒビターの製造方法
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
WO1997003191A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
DE69735421T2 (de) * 1996-04-24 2006-10-19 The Regents Of The University Of Michigan, Ann Arbor Gegen inaktivierung resistenter faktor viii
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
AU735763B2 (en) 1997-12-05 2001-07-12 Immune Response Corporation, The Novel vectors and genes exhibiting increased expression
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
US6586573B1 (en) 1999-02-22 2003-07-01 Baxter International Inc. Albumin-free Factor VIII formulations
ATE310533T1 (de) 1999-07-13 2005-12-15 Zusammensetzungen mit stabilem faktor viii
US6333192B1 (en) 1999-08-09 2001-12-25 North Carolina State University Method of producing an undifferentiated avian cell culture using avian primordial germ cells
US6586574B1 (en) 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
US7282562B2 (en) 1999-08-31 2007-10-16 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2004525608A (ja) 2000-09-19 2004-08-26 エモリー ユニバーシテイ 修飾された因子ｖｉｉｉ
JP4634036B2 (ja) 2001-10-05 2011-02-16 エクスプレッション セラピューティクス， エルエルシー 高レベルエキスプレッサー第ｖｉｉｉ因子ポリペプチドをコードする核酸配列およびアミノ酸配列および使用方法
WO2003047507A2 (en) 2001-11-30 2003-06-12 Emory University Factor viii c2 domain variants
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) * 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1682106A4 (en) 2003-10-30 2008-06-11 Univ Emory MODIFIED FVIII FACTOR WITH REDUCED IMMUNOGENICITY THROUGH MUTAGENESIS OF A2 AND C2 EPITOPES
US7939634B2 (en) 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
ES2449044T3 (es) * 2004-05-03 2014-03-18 Emory University Procedimiento de administración de fVIII sin dominio B porcino
HUE033776T2 (en) * 2004-11-12 2018-01-29 Bayer Healthcare Llc FVIII site-specific modification
EP3231440A1 (en) 2006-12-22 2017-10-18 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
US20090271163A1 (en) * 2007-12-06 2009-10-29 Wyeth Crystal structure of human factor VIII and uses thereof

Also Published As

Publication number Publication date
US9150637B2 (en) 2015-10-06
KR20140114266A (ko) 2014-09-26
ZA201303816B (en) 2021-05-26
MX347503B (es) 2017-04-26
SG10201509149VA (en) 2015-12-30
CO6720990A2 (es) 2013-07-31
DK2635297T3 (da) 2019-05-06
KR101948337B1 (ko) 2019-02-14
US10053500B2 (en) 2018-08-21
ES2721478T3 (es) 2019-07-31
CN103298483A (zh) 2013-09-11
BR112013011041B1 (pt) 2021-05-25
WO2012061689A2 (en) 2012-05-10
MX351220B (es) 2017-10-05
SG190136A1 (en) 2013-07-31
CA2816575A1 (en) 2012-05-10
CN103298483B (zh) 2017-04-12
IL226158A0 (en) 2013-06-27
EP2635297A2 (en) 2013-09-11
WO2012061689A3 (en) 2012-10-04
EA201390654A1 (ru) 2014-01-30
IL226158B (en) 2019-08-29
AU2011323236B2 (en) 2017-03-30
US20150353625A1 (en) 2015-12-10
JP2013545459A (ja) 2013-12-26
JP5922141B2 (ja) 2016-05-24
MX2013005047A (es) 2013-12-06
EP2635297B1 (en) 2019-02-27
CA2816575C (en) 2019-06-11
US20130296244A1 (en) 2013-11-07
EA035447B1 (ru) 2020-06-17
EP2635297A4 (en) 2014-06-25
AU2011323236A1 (en) 2013-06-06
AU2011323236A8 (en) 2013-07-25
MY165089A (en) 2018-02-28

Similar Documents

Publication Publication Date Title
IL267980B (en) A pharmaceutical preparation for the treatment of metabolic syndrome
IL259921B (en) A new stabilizing factor for pharmaceutical proteins
HK1214170A1 (zh) 含有瑞戈非尼的包衣的藥物組合物
HK1201274A1 (en) 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof 33- 19-
IL232914A0 (en) New Azetidine histories, pharmaceutical preparations and their uses
BR112014015042A2 (pt) composição farmacêutica, e, método para obter uma composição radiofarmacêutica
ES2982775T3 (es) Nueva composición farmacéutica
EE201300007A (et) Kombineeritud ravimkoostis diabeedi ning ainevahetush„irete raviks
MX2014010537A (es) Moduladores de receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dermicas.
CU24163B1 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
EE201300004A (et) Kombineeritud ravimkoostis sdame-veresoonkonnaga seotud haiguste v?i seisundite raviks
ZA201302012B (en) Low dose pharmaceutical composition
EP2614821A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ANXIETY DISORDER CONTAINING N-ACETYL-L-CYSTEINE OR A DERIVATIVE THEREOF
EP2588080A4 (en) INJECTABLE PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF JOINTS
BR112013011041A2 (pt) variante de fator viii, polinucleotídeo, vetor de expressão, célula de mamífero, métodos para produzir uma variante de fviii e para tratar um paciente que sofre de hemofilia, e, composição farmacêutica
BR112013013415A2 (pt) composição farmacêutica, e, método para a preparação de uma composição
BR112014011745A2 (pt) composição farmacêutica, e, processo para a fabricação de uma composição farmacêutica de hidrocortisona
EP2926817A4 (en) STABLE PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OSTEOPOROSIS
BRPI1015469A2 (pt) composicao farmaceutica para tratamento do diabetes tipo 2
IL238071B (en) Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cardiovascular disease
HK1178044A1 (en) Pharmaceutical composition for treating drug addiction
BR112013015701A2 (pt) derivado de sulfeto difelina, medicamento e composição farmacêutica contendo o referido derivado
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds
UA21154S (uk) Етикетка для фармацевтичного засобу
EP2789332A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING DIAMINODIPHENYLSULFONE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH BONE MASS REDUCTION

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAXALTA GMBH (CH) , BAXALTA INCORPORATED (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/11/2011, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: BAXALTA INCORPORATED (US) ; BAXALTA GMBH (CH)

Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2652 DE 03/11/2021 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)